Faculty profile

Michael Kennah

ResearcherUniversity of Ottawa

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Ottawa directory, so their courses and email address may be missing. Find their university profile.

Michael Kennah

Researcher

Health Sciences

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
14 publications in the last five years, latest in 2026.
Principal investigator on 1 research grant (1 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Antimicrobial Resistance Biomarker C.Difficile Infection Chimeric Antigen Receptor T-Cell Therapy Feasibility Hematopoietic Stem Cell Transplantation Microbiome Pilot

Latest papers

Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation using Reduced Intensity Conditioning and ATG-based GVHD Prophylaxis.
Transplantation and cellular therapy · 2026
Factors Associated With Prolonged Inpatient Stay in Patients Undergoing Outpatient Allogeneic Stem Cell Transplantation.
Transplantation and cellular therapy · 2026
Late Immune Effector Cell-Associated Hematologic Toxicity After CD19 CAR-T Therapy: Incidence, Clinical Course, and Resource Utilization.
European journal of haematology · 2026

All 14 publications

Latest funding

Oral Vancomycin for the Prevention of C. difficile Infection in High-Risk HCT and CAR-T Patients (VAPOR-HCT): A Pilot Randomized Placebo-Controlled Trial
CIHR · 2025 · Principal investigator
$100,000

All 1 grants and awards

14 publications.

Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation using Reduced Intensity Conditioning and ATG-based GVHD Prophylaxis.

Abduallah Y, Allan D, Atkins H, Bredeson C, Kekre N, Kennah M, Masurekar A, Thyagu S, Nampoothiri RV

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.09.001 PMID: 42700928

Factors Associated With Prolonged Inpatient Stay in Patients Undergoing Outpatient Allogeneic Stem Cell Transplantation.

Koo E, Prince C, Allan D, Atkins H, Bredeson C, Kekre N, Kennah M, Masurekar A, Thyagu S, Vasudevan Nampoothiri R

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.01.036 PMID: 41690552

Late Immune Effector Cell-Associated Hematologic Toxicity After CD19 CAR-T Therapy: Incidence, Clinical Course, and Resource Utilization.

Giguère P, Akbarian N, Prince C, Thavorn K, Cieniak C, Granger M, Hamelin L, Nampoothiri RV, Kennah M, Kekre N

European journal of haematology2026

DOI: 10.1111/ejh.70103 PMID: 41545019

Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence From Machine Learning and Regression Models.

Masurekar AN, Burkett KM, Rahgozar A, Walter RB, Othus M, Abrol K, Mortezaagha P, Thyagu S, Nampoothiri RV, Kennah M, Kekre N, Giguere P, Abduallah Y, Atkins H, Cieniak C, Berardi P, Ramsay T, Mallick R, Carrier M, Bredeson C, Allan D

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2025.12.996 PMID: 41482160

Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment.

Rodriguez-Rodriguez S, Desai N, Chen C, Jamani K, Sohier-Poirier C, Lemieux C, White J, Elemary M, Kennah M, Alfaro Moya T, Al-Shaibani E, Novitzky-Basso I, Pasic I, Law AD, Michelis FV, Viswabandya A, Kumar R, Mattsson J, Kim DDH

British journal of haematology2025

DOI: 10.1111/bjh.70146 PMID: 40947302

Using routine asymptomatic Clostridioides difficile testing to identify patients at high risk of developing C. difficile infection during hematopoietic cell transplantation.

Janusz N, Mortimer L, Leite T, Carroll A, Kekre N, Kennah M, Yan A, Senechal J, Buchan CA, MacFadden D

Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada2025

DOI: 10.3138/jammi-2024-0032 PMID: 41311620

Real-World Selection of Patients for Allogeneic HCT at a Single Centre: Lack of a Suitable Donor and Other Reasons for Not Proceeding.

Monaghan M, Duong A, Abrol K, Doan T, Cieniak C, Atkins H, Kekre N, Masurekar A, Vasudevan Nampoothiri R, Thyagu S, Bredeson CN, Kennah M, Allan DS

Current oncology (Toronto, Ont.)2025

DOI: 10.3390/curroncol32090483 PMID: 41002553

Daratumumab for Posttransplant Autoimmune Hemolytic Anemia.

Abduallah Y, Kennah M, Prince C, Masurekar A, Kekre N, Vasudevan Nampoothiri R

European journal of haematology2025

DOI: 10.1111/ejh.14411 PMID: 40091755

Impact of Day 11 Methotrexate Dose Adjustments due to Mucositis on the Outcomes Following Allogeneic Stem Cell Transplant in the Setting of Anti Thymocyte Globulin (ATG) Based GVHD Prophylaxis.

Dhir V, Prince C, Allan D, Atkins H, Bredeson C, Kekre N, Kennah M, Masurekar A, Vasudevan Nampoothiri R

European journal of haematology2025

DOI: 10.1111/ejh.14380 PMID: 39757868

Distance to CAR-T Treatment Center Does Not Impede Delivery.

Tan XXS, Maltez MT, Mallick R, Hamelin L, McDiarmid S, Cieniak C, Granger M, Bredeson C, Kennah M, Atkins HL, Kekre N

European journal of haematology2025

DOI: 10.1111/ejh.14331 PMID: 39445482

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: Antimicrobial Resistance Dear Professor Kennah, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation using Reduced Intensity Conditioning and ATG-based GVHD Prophylaxis." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Oral Vancomycin for the Prevention of C. difficile Infection in High-Risk HCT and CAR-T Patients (VAPOR-HCT): A Pilot Randomized Placebo-Controlled Trial" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Michael Kennah

Research

Latest papers

Latest funding

Effect of Stem Cell Cryopreservation on Day 60 Donor Chimerism in Unrelated Donor Allogeneic Stem Cell Transplantation using Reduced Intensity Conditioning and ATG-based GVHD Prophylaxis.

Factors Associated With Prolonged Inpatient Stay in Patients Undergoing Outpatient Allogeneic Stem Cell Transplantation.

Late Immune Effector Cell-Associated Hematologic Toxicity After CD19 CAR-T Therapy: Incidence, Clinical Course, and Resource Utilization.

Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence From Machine Learning and Regression Models.

Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment.

Using routine asymptomatic Clostridioides difficile testing to identify patients at high risk of developing C. difficile infection during hematopoietic cell transplantation.

Real-World Selection of Patients for Allogeneic HCT at a Single Centre: Lack of a Suitable Donor and Other Reasons for Not Proceeding.

Daratumumab for Posttransplant Autoimmune Hemolytic Anemia.

Impact of Day 11 Methotrexate Dose Adjustments due to Mucositis on the Outcomes Following Allogeneic Stem Cell Transplant in the Setting of Anti Thymocyte Globulin (ATG) Based GVHD Prophylaxis.

Distance to CAR-T Treatment Center Does Not Impede Delivery.

Oral Vancomycin for the Prevention of C. difficile Infection in High-Risk HCT and CAR-T Patients (VAPOR-HCT): A Pilot Randomized Placebo-Controlled Trial

Frequent collaborators

Natasha Kekre

Harold Atkins

Christopher Bredeson

David Allan

Kednapa Thavorn

Kednapa Thavorn

Jonas Mattsson

Leanne Mortimer

Tommy Alfaro Moya

Derek MacFadden

Rajat Kumar

Marc Carrier

Justin Presseau

Derek MacFadden

Terry Hawrysh

Jennifer Quizi